P/B
1,9
Nautilus Biotechnology
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Company's products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Company's products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
$249.4M
Market Cap • 10/2/2026
2016
(10 years)
Founded
2021
(5 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
1
EPS
—
Market Cap
Market Cap
249,4M
EV
193,2M
EV/Revenue
0
EV/EBITDA
-3,4
EV/EBIT
-3,1
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-0,6%
Total Yield
-0,6%
Payout
0%
Retained Earnings
-361,2M
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
27,2%
Capex/OCF
-3,2%
SBC/OCF
—
% PPE
18,1%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Op. Income 5Y
17,1%
CAGR Net Income 5Y
14,7%
CAGR EPS 5Y
-9,5%
CAGR OCF 5Y
17,3%
Leverage
N.D./EBITDA
1
Debt/Equity
0%
Current Ratio
10,1
Quick Ratio
9,7
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!